# A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

> **NCT05123482** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 460 (estimated)

## Conditions studied

- Breast Cancer
- Biliary Tract Carcinoma
- Ovarian Cancer
- Endometrial Cancer
- Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** AZD8205
- **DRUG:** AZD8205 and AZD2936 (Rilvegostomig)
- **DRUG:** AZD8205 and AZD5305 (saruparib)
- **DRUG:** AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)
- **DRUG:** AZD8205 in combination with AZD9574
- **DRUG:** AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)

## Key facts

- **NCT ID:** NCT05123482
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-18
- **Primary completion:** 2027-09-29
- **Final completion:** 2027-09-29
- **Target enrollment:** 460 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05123482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05123482, "A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05123482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*